Gregory D Ferguson

Summary

Affiliation: Celgene Corporation
Country: USA

Publications

  1. ncbi Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2
    Gregory D Ferguson
    Celgene Corporation, 4550 Towne Center Court, San Diego, CA 92121, USA
    J Clin Immunol 27:210-20. 2007
  2. ncbi Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells
    Laure A Moutouh-de Parseval
    Celgene Corporation, San Diego, California, USA
    J Clin Invest 118:248-58. 2008
  3. ncbi Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
    Dominique Verhelle
    Celgene, San Diego, California 92121, USA
    Cancer Res 67:746-55. 2007
  4. ncbi Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases
    Yibing Xu
    Celgene, San Diego, CA 92121, USA
    Blood 114:338-45. 2009
  5. ncbi Attenuation of ozone-induced airway inflammation and hyper-responsiveness by c-Jun NH2 terminal kinase inhibitor SP600125
    Alison S Williams
    Airway Disease Section, National Heart and Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK
    J Pharmacol Exp Ther 322:351-9. 2007

Collaborators

Detail Information

Publications5

  1. ncbi Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2
    Gregory D Ferguson
    Celgene Corporation, 4550 Towne Center Court, San Diego, CA 92121, USA
    J Clin Immunol 27:210-20. 2007
    ..Taken together, the data in this manuscript suggest CC-4047 will provide important anti-inflammatory benefit to patients and will improve the safety of NSAIDs in the treatment of SCD or other inflammatory conditions...
  2. ncbi Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells
    Laure A Moutouh-de Parseval
    Celgene Corporation, San Diego, California, USA
    J Clin Invest 118:248-58. 2008
    ..These findings support the evaluation of pomalidomide as an innovative new therapy for beta-hemoglobinopathies...
  3. ncbi Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
    Dominique Verhelle
    Celgene, San Diego, California 92121, USA
    Cancer Res 67:746-55. 2007
    ....
  4. ncbi Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases
    Yibing Xu
    Celgene, San Diego, CA 92121, USA
    Blood 114:338-45. 2009
    ..These novel activities provide what we believe a critical mechanism by which IMiDs drugs function as therapeutic immunomodulatory agents...
  5. ncbi Attenuation of ozone-induced airway inflammation and hyper-responsiveness by c-Jun NH2 terminal kinase inhibitor SP600125
    Alison S Williams
    Airway Disease Section, National Heart and Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK
    J Pharmacol Exp Ther 322:351-9. 2007
    ..Inhibition of JNK with small molecule kinase inhibitors may be a means of reducing ozone-induced inflammation and AHR...